EGFR and non-small cell lung carcinoma: A similar trend for earlier use of more potent drugs is currently noted in EGFR-mutated (EGFR+) NSCLC as well, where osimertinib could recently displace earlier TKI as initial treatment for tumors with exon 19 deletions or the L858R mutation [11].